Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience
10 November 2022 - 11:45PM
Business Wire
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical
company developing transformative therapies for the treatment of
brain and nervous system disorders, today announced upcoming poster
presentations at the 52nd Annual Meeting of the Society for
Neuroscience being held November 12-16, 2022 in San Diego, CA. The
presentations include preclinical data supporting the development
of NYX-783, an NMDA receptor positive allosteric modulator in
post-traumatic stress disorder and opioid use disorder.
The poster presentations will be available on the Publications
page of the company’s website at www.aptinyx.com.
NYX-783 Presentation Details:
Presentation Title: Positive allosteric modulator of the
NMDA receptor, NYX-783, reverses repeated stress-induced reduction
of exploration and reduces fear to unpredictable threats in rats
(Poster Number: 560.01) Presenter: Joanna Dabrowska, Ph.D.,
PharmD (Rosalind Franklin University of Medicine and Science)
Poster Presentation: Tuesday, November 15, 2022, 1:00 PM
PT
Presentation Title: Preclinical evaluation of the NMDAR
positive allosteric modulator NYX-783 for opioid use disorder
(Poster Number: 561.05) Presenter: Katie Leaderbrand
(Aptinyx) Poster Presentation: Tuesday, November 15, 2022,
4:00 PM PT
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development, and commercialization of
proprietary synthetic small molecules for the treatment of brain
and nervous system disorders. Aptinyx has a platform for discovery
of novel compounds that work through a unique mechanism to modulate
– rather than block or over-activate – NMDA receptors and enhance
synaptic plasticity, the foundation of neural cell communication.
The company has multiple product candidates in clinical development
in central nervous system indications, including post-traumatic
stress disorder, cognitive impairment associated, and opioid use
disorder. Aptinyx is also advancing additional compounds from its
proprietary discovery platform, which continues to generate a rich
and diverse pipeline of small-molecule NMDA receptor modulators
with the potential to treat an array of neurologic disorders. For
more information, visit www.aptinyx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the company’s business plans and objectives, therapeutic effects of
the company’s product candidates, expectations regarding the
design, implementation, timing, and success of its current and
planned clinical studies, and expectations regarding its uses and
sufficiency of capital. Risks that contribute to the uncertain
nature of the forward-looking statements include: the success,
cost, and timing of the company’s product candidate development
activities and planned clinical studies; the company’s ability to
execute on its strategy; positive results from a clinical study may
not necessarily be predictive of the results of future or ongoing
clinical studies; regulatory developments in the United States and
foreign countries; as well as those risks and uncertainties set
forth in the company’s most recent Annual Report on Form 10-K and
subsequent filings with the Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Aptinyx undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Source: Aptinyx Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221110005493/en/
Investor Contacts: Patrick Flavin Aptinyx Inc.
ir@aptinyx.com 847-871-0377
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptinyx (NASDAQ:APTX)
Historical Stock Chart
From Apr 2023 to Apr 2024